Moderna

Phase A — Understand the business

Lens 1 · Company Overview

Moderna is the leading messenger-RNA (mRNA) medicines platform company — Cambridge, MA, Nasdaq: MRNA, CIK 0001682852, incorporated Delaware. The model: encode a target protein in mRNA, wrap it in a proprietary lipid nanoparticle (LNP), and let the patient's own cells manufacture the antigen/therapeutic. One platform, many shots on goal — vaccines today, oncology and rare disease tomorrow.

What it sells today (3 commercial products): Spikevax and mNEXSPIKE (two COVID vaccines — mNEXSPIKE is a next-gen, one-fifth-dose COVID shot approved May 2025, now "our leading product in the U.S. retail channel"), and mRESVIA (RSV vaccine for older/high-risk adults, approved 40 countries).

The numbers tell the real story. FY2025 total revenue $1.944B, down 40% YoY from $3.236B (FY2024) and down 71% from $6.8B (FY2023). Net product sales $1.818B, of which COVID is $1.810B and RSV just $8M — this is still, overwhelmingly, a COVID-vaccine company whose core product is in structural decline. Net loss $(2.822)B; loss per share $(7.26).

Customers: In the U.S., sold primarily to wholesalers and distributors (and to a lesser extent retailers/providers); ex-U.S., to foreign governments and international organizations (the old advance-purchase-agreement model that is rolling off). Gross-to-net is brutal: FY2025 gross product sales $3.304B → $(1.486)B provisions (wholesaler chargebacks, returns, rebates) → $1.818B net — a ~45% gross-to-net haircut.

Contract structure: A pivot is underway from one-off pandemic APAs toward long-term strategic partnerships with government entities via in-country manufacturing (UK, Canada, Australia — three Moderna-built/managed facilities), plus stand-ready manufacturing revenue (paid to maintain capacity). Other revenue ($126M FY2025) is grants (BARDA, DARPA, Gates Foundation), collaboration (Merck, Vertex), and Japan IP licensing.

The strategy (management's own three priorities): (1) sustain the respiratory franchise; (2) deliver cost efficiency through 2027 (targeting cash breakeven); (3) execute the prioritized pipeline — launch flu, flu+COVID combo, and norovirus to grow the infectious-disease franchise "to as many as six approved products," then reinvest that cash into oncology and rare disease.

Lens 2 · Supply Chain

Upstream inputs → Moderna → end customer, named at each node. mRNA manufacturing is vertically integrated but IP- and single-source-input dependent.

Upstream (inputs & enabling IP):

• Nucleoside/cap chemistry & enzymes — single-source supplier risk is explicitly flagged: "We are dependent on single-source suppliers for some of the components and materials". Lipids for the LNP are a known specialty-chemical chokepoint across the mRNA industry.
• In-licensed IP (the real upstream dependency): Cellscript/mRNA RiboTherapeutics (modified-nucleoside patents), NIAID/NIH (RSV + spike-stabilization patents — $10M paid Jan 2025 for RSV rights, low-single-digit royalties), and — until the March 2026 settlement — Arbutus/Genevant for the LNP delivery tech. Royalty stack is heavy: FY2025 third-party royalties $88M in COGS.

Midstream (Moderna manufacturing): Vertically integrated — Moderna Technology Center (Norwood, MA; finance-leased then acquired Dec 2024), Marlborough, MA purpose-built for intismeran (began clinical batch supply Sept 2025), plus the UK/Canada/Australia in-country plants. Intismeran is the chokepoint: it is "uniquely manufactured for each patient using a novel, complex manufacturing process" — a bespoke, per-patient supply chain that does not scale like a vial of vaccine.

Downstream (route to patient): Moderna → U.S. wholesalers/distributors (McKesson, Cardinal, Cencora-class — not named in filing but the standard U.S. pharma channel) → retail pharmacies / providers → patient; ex-U.S. → national governments / WHO-type organizations. For oncology, Merck (pembrolizumab/KEYTRUDA) is the indispensable co-development and combination partner — intismeran has no path to market without Merck.

Chokepoints & single-source dependencies: (1) specialty lipids + nucleoside enzymes (single-source, named risk); (2) the LNP IP (now de-risked operationally by the Arbutus settlement, but at a $950M + up to $1.3B contingent cost — see Lens 10); (3) per-patient intismeran manufacturing (the binding constraint on the oncology launch if approved); (4) government reimbursement / ACIP recommendation as the true downstream gate — a vaccine the CDC doesn't recommend is a vaccine insurers don't fully cover (Lens 10/13).

Lens 3 · Competitive Advantages (moats)

The moat is the platform + the manufacturing + the IP estate — partly real, partly contested.

• Platform / process moat (real but commoditizing): Moderna's edge is speed-to-candidate and a repeatable mRNA-to-clinic process — it can spin up a new antigen faster than legacy protein-vaccine players. mNEXSPIKE (one-fifth the Spikevax dose, 13.5% relative vaccine efficacy vs Spikevax in 65+) is genuine platform progress. But BioNTech/Pfizer hold the other half of mRNA — this is a duopoly in mRNA vaccines, not a monopoly.
• IP estate (a sword AND a liability): Moderna is simultaneously plaintiff (suing Pfizer/BioNTech in the U.S., Germany, Netherlands, UK, Ireland, Belgium over mRNA platform patents) and defendant (GSK suing on LNP/liposome patents; Northwestern University suing; just settled Arbutus/Genevant). A moat you have to litigate from both sides is a contested moat.
• Bargaining power — weak and weakening. Over customers: governments walked away from APAs and U.S. retail demand is price-sensitive and policy-gated; the ~45% gross-to-net haircut shows Moderna is a price-taker, not a price-maker. Over suppliers: dependent on single-source inputs and in-licensed core IP (royalty obligations to Cellscript, NIAID). The one place power is real: oncology via intismeran, where a positive Phase 3 in adjuvant melanoma would create a first-in-class, hard-to-replicate, patent-and-data-protected asset.
• The honest read: the durable moat is not COVID vaccines (declining, duopolistic, policy-exposed). It is (a) the platform's option value across many indications and (b) intismeran's potential first-mover lead in individualized neoantigen therapy. Both are bets on the future, not a present-day economic castle.

Lens 4 · Segments

Moderna reports as a single operating segment; disaggregation is by product and by geography only.

Net product sales by product (FY, $M):

. Read: COVID is ~99.6% of product revenue and falling ~41% per year. RSV launched into disappointment — $8M in FY2025 (down from $25M!) after ACIP recommendations came in "more limited than anticipated". The growth segments (flu, combo, norovirus, oncology) currently contribute $0 in product revenue.

Net product sales by geography (FY, $M):

. Read: Europe collapsed 91% (573→50) as government APAs completed; ROW down on the same dynamic, partly offset by the new in-country manufacturing partnerships. The U.S. is now ~64% of product sales and is the most policy-exposed dollar of all (see Lens 10).

Trend & cause: Decelerating across the board on the COVID base; the bull thesis requires the mix to flip — new infectious-disease launches (flu PDUFA Aug 5 2026; combo; norovirus) to stabilize the top line in 2026 (management guides ~10% revenue growth ) and oncology to provide the step-change later.

Phase B — Measure performance

Lens 5 · Earnings Result (latest print + FY2025)

FY2025 (10-K, filed 2026-02-20): Total revenue $1.944B (−40%); cost of sales $868M (48% of net product sales — inflated by $291M inventory write-downs + $93M unutilized-capacity/wind-down); R&D $3.132B (−31%); SG&A $1.018B (−13%); total opex $5.018B (−30%); loss from operations $(3.074)B; interest income $314M; net loss $(2.822)B, EPS $(7.26). The cost line is the good news — management cut ~$2B of opex in 2025, "significantly exceeding" its commitment.

Latest print — Q1 2026 (10-Q, filed 2026-05-01):

. The headline beat masks a worse bottom line. Revenue tripled (Europe jumped $0→$239M on the in-country/combo dynamic; mNEXSPIKE ramp), yet net loss WIDENED by $372M — because Q1 carried $876M of the Arbutus/Genevant settlement in cost of sales (royalty expense $895M in the quarter vs $5M a year earlier). Strip the one-time settlement and the operating trajectory is genuinely improving; report it as-is and the quarter is ugly. Seasonality matters: COVID is a Q3/Q4 business — Q1 is structurally the weakest quarter, so a $389M Q1 is not annualizable.

Balance-sheet flags: Cash + investments $8.135B at FY2025-end (down $1.4B YoY), $7.456B at Q1-end (cash $1.908B + securities). FY2025 operating cash burn $(1.873)B; Q1 2026 net cash decrease $(688)M. Receivables falling with revenue (clean). New debt: a Nov-2025 $1.5B Ares-led senior secured term loan ($600M drawn at ~9.17%, secured by substantially all assets, $500M minimum-cash covenant) — a notable choice to take expensive secured leverage while sitting on $8B of cash (Lens 10).

Market reaction / what's priced: Despite the loss, MRNA is up ~94% YTD in 2026, trading ~$55.80 (Jun 17) vs an analyst median target of $45 and a consensus that has drifted to "Reduce". The market is pricing the pipeline (intismeran ASCO data, cost cuts), not the print.

Lens 6 · Earnings Calls / Communications (sentiment trend)

No transcripts/ on the shelf; grounded from filings' MD&A + public coverage.

Tone arc over the last ~4 quarters: The management narrative has shifted decisively from "defend COVID revenue" (2024) → "cost discipline + cash breakeven" (2025) → "return to growth + pipeline catalysts" (2026). The recurring phrases now are "cost efficiency," "prioritized pipeline," "cash breakeven," and "return to growth in 2026." Bancel at JPM 2026 reiterated ~10% revenue growth and framed Moderna as building a seasonal respiratory franchise (flu, combo, RSV, COVID) funding an oncology/rare-disease pivot.

What they stopped saying: the pandemic-era "$X billion in APAs" language is gone; so is bullish CMV talk (the congenital-CMV Phase 3 failed Oct 2025). What they started saying: AI/cost ("leverage AI and digital tools to improve cost efficiency"; the OpenAI/ChatGPT-Enterprise deployment is now a stated productivity lever) and "post-marketing commitments" (a tell that approvals are coming with strings). Net sentiment: cautiously constructive, execution-dependent — credible on cost, unproven on the revenue flip.

Lens 7 · Comps (peer table)

Peer set: the mRNA/COVID-vaccine cohort.

. Read: On any earnings-based multiple Moderna is not measurable (it loses money). On EV/Sales it screens most expensive of the cohort relative to a shrinking, lossmaking top line — its ~$19.7B cap on ~$2B of declining revenue is an option premium on the pipeline, not a multiple on the business. BioNTech, by contrast, trades at ~7x forward earnings with a fortress balance sheet — the market is paying far more for Moderna's story than for BioNTech's cash flows. That relative-value gap is the single sharpest fact in this dossier.

Lens 8 · Stock-Price Catalysts (what moves MRNA >5%)

Pattern over the COVID-to-now arc:

• 2021 peak ~$485 → 2026 ~$56: down ~90% from the all-time high. The dominant multi-year move is the COVID-revenue cliff — APAs rolling off, demand normalizing.
• +94% YTD 2026 — driven by (a) intismeran ASCO 5-yr data (Jun 1 2026) — 49% reduction in recurrence/death, 59% reduction in distant metastasis vs KEYTRUDA alone; (b) the ~$2B cost-cut beat; (c) European approvals (mCOMBRIAX combo). A +6% single-day pop on May 11 2026.
• Down-moves cluster on: ACIP/FDA policy (RSV recommendation disappointment; RFK/HHS pulling COVID recs), trial failures (congenital-CMV Oct 2025), and the flu Refusal-to-File letter.

What the market actually reacts to for this name: (1) pipeline binary events (oncology data, PDUFA dates), and (2) U.S. vaccine policy (ACIP/FDA/RFK). Earnings prints matter less than catalysts — this trades like a development-stage biotech with a COVID cash annuity attached, not like a commercial pharma.

Phase C — Judge people & books

Lens 9 · Management

• CEO Stéphane Bancel (founder-CEO since 2011, pre-IPO): the defining figure. Track record: built Moderna from platform thesis to the fastest COVID-vaccine ramp in history (0→$18B+ revenue in 2021–22) — a genuinely historic execution. The flip side: presided over the ~90% drawdown and has not yet proven a second act — every non-COVID commercial product (RSV $8M; flu RFL'd; CMV failed) has so far disappointed.
• Skin in the game: Bancel remains a large individual shareholder (founder stake) — alignment is real on the upside. But comp optics are poor: FY2025 total pay $19.9M with a cash bonus up ~120% to $4.3M — the highest bonus since IPO — in a year the stock was near multi-year lows and the company lost $2.8B. Paying the biggest cash bonus ever during the trough is a governance yellow flag.
• Capital allocation: Mixed-to-poor on the scoreboard. ROE/ROIC deeply negative (net loss $(2.8)B on ~$8B equity). The pandemic-era buybacks (repurchasing stock at far higher prices) destroyed value in hindsight. The Nov-2025 decision to take a $1.5B secured term loan at ~9% while holding $8B cash is hard to defend on cost-of-capital grounds — it reads as either covenant-driven liquidity insurance or a signal management wants dry powder it didn't want to raise via equity at $40. The $950M Arbutus settlement (plus up to $1.3B contingent) is the cost of an LNP-IP position that was never fully owned.
• Red flags: the bonus-in-a-trough; the secured-debt-on-a-cash-pile; repeated guidance resets. Founder vs professional: a visionary founder-operator — the right archetype to have invented the platform, an open question on whether he's the right one to run the disciplined, payer-by-payer commercial grind the next phase demands.

Lens 10 · Forensic Red Flags

Forensic-analyst lens across income statement, balance sheet, cash flow. Every figure labeled.

• Cash vs earnings divergence (favorable direction, watch the trend): FY2025 net loss $(2.822)B but operating cash burn only $(1.873)B — the gap is non-cash (SBC, write-downs, working-capital releases). Not a red flag per se, but the cumulative burn is the clock: ~$1.9B/yr against ~$7.5B cash ≈ ~3–4 years of runway before the $950M Arbutus payment (due Q3 2026) and before any contingent $1.3B.
• Inventory write-downs as recurring "one-timers": $291M (FY2025) + $93M unutilized capacity, after $495M + $368M in FY2024. Two straight years of large write-downs and wind-down costs means demand forecasting has repeatedly missed — quality-of-COGS is poor and these "non-recurring" charges keep recurring.
• Revenue recognition / returns reserve — flagged by the auditor. Ernst & Young designated provisions for product-sales returns a Critical Audit Matter: the estimate "relies on management's assumptions regarding inventory remaining in the distribution channel… and the Company has limited historical returns on which to base its assumptions". With a ~45% gross-to-net and a $216M prior-year provision adjustment in FY2024, the returns reserve is the most judgment-laden, most-watchable line.
• SBC: $104M in Q1 2026 (down from $115M); $978M unrecognized, ~2.9yr vesting. Material but not flattering non-GAAP (Moderna reports GAAP losses anyway).
• The $1.5B secured term loan (Ares, Nov 2025): ~9.17% rate, first-priority lien on substantially all assets, minimum-cash covenant ($500M, rising to $750M if >$1B drawn; waived if 30-day-avg market cap > $5B). Expensive, secured, covenant-bound debt on top of $8B cash is the single most curious capital-structure choice and deserves a direct management question (Lens 14).
• Goodwill/intangibles: small ($52M goodwill; $116M finite-lived intangibles incl. the $72M Arbutus-license capitalization) — low impairment risk.

Regulatory findings (required sub-section):

• SEC Litigation Releases / AAERs: None. "No LR found" and "No AAER found" for Moderna 2021-06-18 → 2026-06-18 via SEC EDGAR EFTS.
• 10-K Item 3 / Legal Proceedings (the live exposure): This is where the risk is. (1) Arbutus/Genevant — settled Mar 3 2026, $950M lump sum payable Q3 2026 ($876M to COGS, $74M capitalized), resolving worldwide LNP-IP litigation with no future royalties — BUT Moderna appealed the §1498 (U.S.-government-use) ruling to the Federal Circuit and could owe an additional up to $1.3B depending on the outcome; no accrual taken (loss not "probable"). (2) Moderna offensive patent suits vs Pfizer/BioNTech across 6 jurisdictions. (3) GSK suing Moderna (LNP/liposome patents, U.S. + UPC). (4) Northwestern University suing Moderna. The IP war is two-directional and unresolved.
• Non-SEC enforcement (web): No material FTC/DOJ/FDA enforcement action found against Moderna. The material regulatory exposure is policy, not enforcement — the RFK Jr./HHS dismantling of ACIP, "no functioning CDC," withdrawal of COVID recommendations for children/pregnancy, and a May-2025 "most-favored-nation" drug-pricing executive order all directly threaten Moderna's recommended-and-reimbursed status. VRBPAC was scheduled to vote on mRNA-1010 (flu) on June 18, 2026 — the regulatory gate ahead of the Aug 5 PDUFA.
• Verdict: No accounting-fraud signal (clean SEC record, Big-4 auditor, GAAP losses honestly reported). The forensic risk is concentrated in (a) the returns-reserve judgment (CAM), (b) recurring inventory write-downs, and (c) the off-balance-sheet $1.3B contingent IP liability. The existential risk is policy/reimbursement, not the books.

Phase D — Project & stress-test

Lens 11 · Forward Projection (FY2026 / FY2027 / FY2028 EPS — base / bull / bear)

Bottom-up from FY2025 actuals + 2026 guidance. Every input labeled; outputs ``. Did NOT run forecast.ts create (watchlist loop). Note: Moderna is loss-making — the scoreable question is the trajectory to cash breakeven, not a positive EPS print.

Anchors: FY2025 revenue $1.944B, net loss $(2.822)B / EPS $(7.26); ~395M diluted shares (Q1'26). 2026 guide: 10% revenue growth → **$2.1B**; GAAP opex ~$4.9B.

Base case — flu (mRNA-1010) approved on the Aug 5 PDUFA but small first season; combo/RSV modest; oncology pre-revenue; cost cuts hold opex ~$4.9B FY2026 then ~$4.3B FY2027:

• FY2026 rev ~$2.1B, opex ~$4.9B → loss from ops ~$(2.8)B + interest income ~$0.3B − Arbutus $950M (already largely in COGS) → EPS ~$(6.0).
• FY2027 rev ~$2.6B, opex ~$4.3B → EPS ~$(4.0).
• FY2028 rev ~$3.2B, opex ~$4.2B → EPS ~$(2.3). Cash breakeven not reached by 2028 in the base case.

Bull case — flu approved + recommended, norovirus Phase 3 positive, intismeran Phase 3 adjuvant melanoma positive in 2026 → first oncology launch ~2027–28; opex flat ~$4.2B:

• FY2026 EPS ~$(5.3); FY2027 rev ~$3.2B, EPS ~$(2.5); FY2028 rev ~$4.5B (oncology ramp), EPS approaching ~$(0.5) — near cash breakeven. This is the path that justifies a $19.7B cap.

Bear case — flu RFL'd again or approved-but-not-recommended (RFK/ACIP), COVID continues to erode, norovirus misses on case accrual, intismeran Phase 3 disappoints:

• FY2026 rev ~$1.8B (flat-to-down), EPS ~$(6.5); FY2027 rev ~$1.6B, EPS ~$(6.0); FY2028 rev ~$1.5B, EPS ~$(5.5). Burn continues ~$2B/yr → the $1.3B contingent + ongoing burn pressures the ~$7.5B cash toward a dilutive raise by ~2028–29.

Brier forecast I would log (not logged here): "MRNA reaches GAAP operating cash breakeven by FY2028, p≈0.30" and "intismeran Phase 3 adjuvant melanoma primary endpoint met (RFS), p≈0.60" — the second is the asymmetric one.

Lens 12 · Bull vs Bear

Bull case. Moderna is a platform option, not a vaccine stock, and the option is finally moving into the money. (1) Intismeran — the 5-yr Phase 2b melanoma data (49% RFS benefit, 59% distant-metastasis benefit vs KEYTRUDA alone) is the strongest individualized-neoantigen dataset in existence; a positive Phase 3 in 2026 would create a first-in-class, Merck-partnered, multi-tumor franchise with peak-sales potential in the multiple-billions. (2) The cost story is real and beating — ~$2B opex cut in 2025, opex guided to ~$4.9B, a credible march toward cash breakeven. (3) Six-product respiratory franchise by ~2027 (flu Aug-5 PDUFA, combo mCOMBRIAX already approved in Europe, norovirus Phase 3) stabilizes the base and funds the pivot. (4) $7.5B liquidity buys years of runway. (5) Optionality across rare disease (the Merck/Vertex collaborations, the platform itself). The contrarian-bull read: the market still prices this as a dying COVID name; it's actually an oncology + multi-vaccine platform whose worst year (revenue trough) is behind it.

Bear case (2–3 permanent-impairment risks). (1) U.S. vaccine policy could structurally de-rate the entire mRNA-vaccine TAM — RFK Jr./HHS gutting ACIP, withdrawing recommendations, "no functioning CDC," MFN pricing pressure: if mRNA vaccines lose recommended-and-reimbursed status in the U.S., the respiratory franchise that's supposed to fund everything is impaired at the source. (2) The second act may simply not arrive at scale — RSV launched to $8M, CMV failed, flu got an RFL; a track record of non-COVID commercial disappointment is data, not noise. (3) Perpetual cash burn + the $1.3B IP tail — if intismeran disappoints and the franchise stalls, the ~$2B/yr burn plus contingent liabilities forces dilution from a depressed price.

Pre-mortem (18 months out, thesis broke): It's late 2027. Intismeran's Phase 3 adjuvant-melanoma readout missed or was ambiguous; the flu vaccine was approved but ACIP (post-RFK) declined to recommend it, so U.S. uptake was minimal; COVID kept eroding; the Federal Circuit ruled against Moderna on §1498 and the $1.3B came due. The stock that ran to $56 on hope round-tripped to the $20s. The mechanism: the +94% melt-up priced the oncology win before it happened, and the policy + execution risks the bulls waved away showed up together.

Are multiples too high? On the business as it exists today — a lossmaking, shrinking, policy-exposed vaccine company — yes, demonstrably: the stock trades ABOVE the analyst median target ($45) with a consensus drifting to "Reduce". On the option value of intismeran + the platform, it is defensible only if you underwrite a positive Phase 3. The market is currently refusing to see how binary the next 12 months are: this is not a "transition" story you can dollar-cost into — it's a coin-flip on an oncology endpoint and a coin-flip on U.S. vaccine policy, stacked.

Lens 13 · Devil's Advocate (short-seller)

Dismantling the bull case.

• Where revenue is concentrated, and the shift: ~99.6% of product revenue is COVID, ~64% U.S. The single most dangerous shift is already in motion — U.S. vaccine policy turning hostile. A vaccine company whose core product the government may stop recommending is short the most important variable it doesn't control.
• Why the moat is weaker than bulls think: mRNA vaccines are a duopoly with Pfizer/BioNTech, and Moderna is litigating the LNP IP from a defensive crouch (GSK, Northwestern) having just paid $950M to settle one front with up to $1.3B still contingent. A moat you rent (Cellscript/NIAID royalties) and litigate is not a moat — it's a toll road you don't fully own.
• Most dangerous competitor bulls underestimate: BioNTech — fortress balance sheet (€17.2B cash), profitable-ish, the only mRNA peer growing revenue, and pursuing the same oncology pivot at ~7x forward earnings vs Moderna's "n/m, priced on hope". If you want mRNA oncology optionality, BioNTech offers it cheaper and safer.
• Worst capital-allocation moves: pandemic-peak buybacks (value-destroyed); a $19.9M CEO package with a record cash bonus in the trough year; a $1.5B secured loan at ~9% on top of $8B cash. None of these inspire confidence in the steward of $7.5B.
• What must hold for $56: flu approved and recommended; norovirus Phase 3 hits; intismeran Phase 3 hits; cost cuts continue; policy doesn't break the U.S. franchise; the $1.3B contingent doesn't land. That's ~6 things, several binary, several outside management's control.
• If growth disappoints 20–30%: there's no earnings to compress (already lossmaking) — the de-rating comes through the option value collapsing. A missed intismeran Phase 3 alone could halve the equity, because that's most of what's holding the ~$19.7B cap above the ~$8B net cash.
• Single permanent-impairment scenario, and plausibility: U.S. structurally de-recommends mRNA vaccines (ACIP/HHS) AND intismeran Phase 3 misses — twin failures of the funding base and the growth engine. Individually plausible (policy risk is live today; Phase 3 oncology endpoints fail often); jointly, perhaps 15–25% — high enough to demand a margin of safety this price doesn't offer.

Lens 14 · Management Questions (ordered by information value)

1. Intismeran Phase 3 adjuvant melanoma — exact expected readout timing in 2026, the pre-specified primary endpoint and success bar (RFS hazard ratio), and what you'll do commercially the day it reads out positive vs negative?
2. On the §1498 Federal Circuit appeal, what is the realistic probability-weighted range of the additional up to $1.3B Arbutus/Genevant payment, and how is it provisioned across scenarios?
3. Given $7.5B+ in cash, why take a $1.5B secured term loan at ~9% — what scenario were you insuring against, and does it signal you won't raise equity at these prices?
4. If ACIP (post-reconstitution) declines to recommend mRNA-1010 flu after an Aug-5 approval, what is your U.S. commercial plan, and what % of the flu opportunity is contingent on a recommendation?
5. Walk through the bridge to cash breakeven — the year, the revenue level, and the opex level required, and which is the bigger lever.
6. RSV did $8M in FY2025. What specifically went wrong, and what does it teach you about launching flu/combo/norovirus into a hostile policy environment?
7. What is the realistic peak-sales and gross-margin profile of a per-patient intismeran given its bespoke Marlborough manufacturing — can individualized therapy ever carry vaccine-like margins?
8. How exposed is your respiratory franchise to the May-2025 most-favored-nation pricing executive order, quantitatively?
9. With CMV-congenital failed, what is the go/no-go logic keeping the transplant-CMV and other rare-disease programs funded versus returning capital?
10. mNEXSPIKE is now your "leading U.S. retail product" — what are its unit economics vs Spikevax, and is the one-fifth dose a margin story or just a volume story?
11. What share of FY2026's guided ~10% growth is durable (in-country partnerships, new launches) vs a low-base/seasonality artifact?
12. On governance: justify the record FY2025 cash bonus against a $2.8B loss and a multi-year-low share price.
13. How real is the AI/OpenAI cost lever — quantify the opex savings attributable to it in 2025, separate from headcount cuts.
14. What is your norovirus Phase 3 case-accrual contingency if the 2025-26 Northern Hemisphere season again under-enrolls?
15. Five years out, is Moderna a respiratory-vaccine company that does oncology, or an oncology/rare-disease company that happens to sell vaccines — and which P&L should we model?